KRAS and Obesity: In this review, we will focus on the interplay of obesity (e.g., adipose tissue dysfunction and meta-inflammation), oncogenic KRAS, and metabolic and inflammatory regulators, in particular FGF21, a novel anti-obesity and anti-inflammation factor, in the development of PDAC.